Tirzepatide 5mg

1. What is Tirzepatide?

Tirzepatide is a novel dual-incretin peptide that acts as both a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It was developed to treat type 2 diabetes and obesity by enhancing insulin secretion, reducing appetite, and improving glycemic control. Tirzepatide offers a new therapeutic approach by combining the effects of two key incretin hormones in a single molecule.

2. Tirzepatide Structure

【pictures linking，https://pubchem.ncbi.nlm.nih.gov/compound/156588324】

Amino Acid Sequence: YE-Aib-GTFTSDYSI-Aib-LDKIAQ (C20 fattyacid)AFVQWLIAGGPSSGAPPPS

Note: Aib is a non-coded (non-proteinogenic) amino acid – H2H-C(CH3)2-COOH

Molecular Formula:C225H348N48O68

Molecular Weight: 4813.527 g/mol

PubChem ClD:156588324

CAS Number:2023788-19-2

Synonyms: P1206,LY3298176

3. Tirzepatide Research

Tirzepatide is a groundbreaking dual GIP–GLP-1 receptor agonist, ingeniously designed to harness the synergistic effects of both incretins. This co-agonist leverages GIP-mediated metabolic efficiency and GLP-1-mediated appetite suppression, enabling a new plateau in weight and glucose management.

Key Mechanistic Highlights

GIP component enhances insulin sensitivity and amplifies weight-independent metabolic actions.

GLP-1 component delays gastric emptying, promotes satiety, and enhances insulin secretion—while suppressing glucagon.

The lipidated peptide binds albumin, ensuring a ~5-day half-life for once-weekly dosing 【https://en.wikipedia.org/wiki/Tirzepatide?utm_source=chatgpt.com】.

Efficacy in Obesity (SURMOUNT & Other Trials)

SURMOUNT-1 (72 weeks): 15 mg weekly led to −20.9% body weight, with superior waist reduction vs placebo 【https://medschool.uci.edu/news/uc-irvine-researchers-project-cardiac-benefits-weight-loss-medication-tirzepatide?utm_source=chatgpt.com】【https://www.nejm.org/doi/full/10.1056/NEJMoa2206038?utm_source=chatgpt.com】.

Comparative Advantage: In a head-to-head with semaglutide, tirzepatide delivered 20.2% vs 13.7% weight loss, affirming its dual agonist edge .

Cardiometabolic Outcomes

In T2D cohorts, tirzepatide reduced HbA1c by ~2.4% and body weight by up to 11 kg【https://pmc.ncbi.nlm.nih.gov/articles/PMC7843845/?utm_source=chatgpt.com】.

Real-world data show it’s linked to slowed eGFR decline and improved kidney outcomes 【https://www.jacc.org/doi/10.1016/j.jacadv.2025.101740?utm_source=chatgpt.com】.

ASCVD Risk Reduction: Estimated 10-year cardiovascular risk significantly declined in obese/non-diabetic users 【https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.15318?utm_source=chatgpt.com】.

Body Composition & Labs

A recent metabolic study showed –33.9% fat mass reduction vs placebo 【https://en.wikipedia.org/wiki/Tirzepatide?utm_source=chatgpt.com】.

Tirzepatide fosters healthy lipid shifts (↓ triglycerides, LDL; ↑ HDL, adiponectin) .

Oncology & Neurocognitive Emerging Data

Mouse breast-cancer studies at ENDO 2025 revealed ~20% weight loss and smaller tumors, suggesting anti-cancer potential .

Observational research relates dual-agonist use to 37% less dementia, 19% fewer strokes, and 30% reduction in mortality 【https://www.thesun.co.uk/health/35857509/ozmepic-fat-jabs-weight-loss-dementia-stroke/?utm_source=chatgpt.com】.

✅ Why Consider Tirzepatide?

💥 Transformational weight loss: Delivers ~21% reduction—industry-leading outcomes for obesity.

🧬 Comprehensive metabolic control: Simultaneous improvements in glycemic status, lipids, and body fat distribution.

🫀 Cardio–renal protection: Beneficial outcomes in HFpEF, CKD markers, and predicted ASCVD risk.

🧠 Potential neuro-oncology advantages: Early signals in cognitive decline and tumor biology attenuation.

🛠 Mechanistic sophistication: Dual-incretin design outperforms GLP-1 monotherapy.

🌍 Broad evidence base: From pediatric diabetes to large ACC/UC Irvine modeling on public health impact【https://www.acc.org/About-ACC/Press-Releases/2025/03/31/13/01/Tirzepatide-Benefits-People-with-Obesity?utm_source=chatgpt.com】.

4. Future Tirzepatide Research

• Non-Diabetic Obesity Trials
  Expanded trials will evaluate long-term outcomes in metabolic health and chronic disease prevention.
• Cardiorenal Outcomes (SUMMIT, SELECT)
  Key data on HFpEF, CKD, and ASCVD to validate emerging benefits 【https://www.acc.org/About-ACC/Press-Releases/2025/03/31/13/01/Tirzepatide-Benefits-People-with-Obesity?utm_source=chatgpt.com】.
• Neurocognitive and Oncology Research
  Follow-up mouse findings are prompting human dysmetabolic and cancer-adjunct studies 【https://en.wikipedia.org/wiki/Tirzepatide?utm_source=chatgpt.com】.
• Mechanistic Biomarker Arrays
  Deep phenotyping will identify responders and explore adipokine, inflammatory, and tissue remodeling pathways.
• Combination & Precision Medicine Approaches
  Investigating synergy with agents like cagrilintide and custom metabolic phenotyping 【https://en.wikipedia.org/wiki/Cagrilintide/semaglutide?utm_source=chatgpt.com】.

5. Application Areas

✅ Summary

Tirzepatide breaks new ground with dual-receptor incretin activation, delivering record-breaking weight loss, unmatched metabolic support, and emerging cardio–renal and neuro-oncological benefits. Its multi-faceted clinical impact—spanning from routine metabolic care to complex comorbidity profiles—reinforces its position as a versatile and powerful tool in modern wellness and chronic disease management.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies(Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.